Alligator Bioscience AB (publ) (ATORX.ST)
SEK 6.3
(-3.37%)
SEK 6.3
(-3.37%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 118.45 Million SEK | -30.15% |
| 2022 | 169.58 Million SEK | -49.1% |
| 2021 | 333.2 Million SEK | 119.3% |
| 2020 | 151.93 Million SEK | -51.17% |
| 2019 | 311.12 Million SEK | -38.77% |
| 2018 | 508.15 Million SEK | -20.98% |
| 2017 | 643.03 Million SEK | -8.24% |
| 2016 | 700.78 Million SEK | 68.35% |
| 2015 | 416.25 Million SEK | 325.65% |
| 2014 | 97.79 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 87.77 Million SEK | -25.9% |
| 2024 Q3 | 91.77 Million SEK | -23.88% |
| 2024 Q2 | 120.55 Million SEK | 37.35% |
| 2023 FY | 118.45 Million SEK | -30.15% |
| 2023 Q2 | 223.95 Million SEK | 83.47% |
| 2023 Q1 | 122.06 Million SEK | -28.02% |
| 2023 Q3 | 184.1 Million SEK | -17.79% |
| 2023 Q4 | 118.45 Million SEK | -35.66% |
| 2022 Q2 | 251.45 Million SEK | -14.77% |
| 2022 FY | 169.58 Million SEK | -49.1% |
| 2022 Q4 | 169.58 Million SEK | -17.3% |
| 2022 Q3 | 205.05 Million SEK | -18.45% |
| 2022 Q1 | 295.02 Million SEK | -11.46% |
| 2021 Q4 | 333.2 Million SEK | 152.77% |
| 2021 FY | 333.2 Million SEK | 119.3% |
| 2021 Q3 | 131.82 Million SEK | -15.2% |
| 2021 Q2 | 155.45 Million SEK | -18.91% |
| 2021 Q1 | 191.7 Million SEK | 26.17% |
| 2020 Q4 | 151.93 Million SEK | -19.01% |
| 2020 Q2 | 222.11 Million SEK | -14.45% |
| 2020 FY | 151.93 Million SEK | -51.17% |
| 2020 Q1 | 259.62 Million SEK | -16.56% |
| 2020 Q3 | 187.59 Million SEK | -15.54% |
| 2019 FY | 311.12 Million SEK | -38.77% |
| 2019 Q4 | 311.12 Million SEK | -16.31% |
| 2019 Q3 | 371.74 Million SEK | -11.67% |
| 2019 Q2 | 420.84 Million SEK | -10.1% |
| 2019 Q1 | 468.12 Million SEK | -7.88% |
| 2018 Q4 | 508.15 Million SEK | -3.29% |
| 2018 Q3 | 525.46 Million SEK | -7.02% |
| 2018 Q2 | 565.15 Million SEK | -5.62% |
| 2018 Q1 | 598.81 Million SEK | -6.88% |
| 2018 FY | 508.15 Million SEK | -20.98% |
| 2017 Q1 | 676.61 Million SEK | -3.45% |
| 2017 Q3 | 626.91 Million SEK | -3.97% |
| 2017 FY | 643.03 Million SEK | -8.24% |
| 2017 Q2 | 652.83 Million SEK | -3.51% |
| 2017 Q4 | 643.03 Million SEK | 2.57% |
| 2016 FY | 700.78 Million SEK | 68.35% |
| 2016 Q4 | 700.78 Million SEK | 82.83% |
| 2016 Q3 | 383.3 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2015 Q4 | 416.25 Million SEK | 0.0% |
| 2015 FY | 416.25 Million SEK | 325.65% |
| 2014 FY | 97.79 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 93.768% |
| AcouSort AB (publ) | 34.51 Million SEK | -243.204% |
| Active Biotech AB (publ) | 44 Million SEK | -169.205% |
| Alzinova AB (publ) | 123.18 Million SEK | 3.847% |
| Amniotics AB (publ) | 26.08 Million SEK | -354.075% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -1849.153% |
| BioArctic AB (publ) | 1.18 Billion SEK | 90.013% |
| Camurus AB (publ) | 1.9 Billion SEK | 93.791% |
| Cantargia AB (publ) | 223.71 Million SEK | 47.052% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -696.624% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -292.569% |
| Genovis AB (publ.) | 288.85 Million SEK | 58.994% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -38.982% |
| Mendus AB (publ) | 755.95 Million SEK | 84.331% |
| Kancera AB (publ) | 65.64 Million SEK | -80.446% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 90.587% |
| LIDDS AB (publ) | 17.65 Million SEK | -570.915% |
| Lipum AB (publ) | 12.11 Million SEK | -878.117% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -252.509% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 57.506% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -491.038% |
| NextCell Pharma AB | 81.28 Million SEK | -45.716% |
| OncoZenge AB (publ) | 20.34 Million SEK | -482.35% |
| Saniona AB (publ) | 64.14 Million SEK | -84.666% |
| Simris Alg AB (publ) | 174.55 Million SEK | 32.141% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 76.131% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 81.875% |
| Xintela AB (publ) | 18.39 Million SEK | -543.925% |
| Ziccum AB (publ) | 14.97 Million SEK | -691.143% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 15.752% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 84.522% |
| CombiGene AB (publ) | 120.61 Million SEK | 1.793% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 45.424% |
| Intervacc AB (publ) | 259.61 Million SEK | 54.374% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -89.894% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -182.299% |
| Corline Biomedical AB | 100.1 Million SEK | -18.326% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 33.125% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -90.581% |
| Aptahem AB (publ) | 63.02 Million SEK | -87.941% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 66.286% |
| Fluicell AB (publ) | 9.34 Million SEK | -1168.201% |
| Biovica International AB (publ) | 131.4 Million SEK | 9.861% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -123.554% |
| Abliva AB (publ) | 87.49 Million SEK | -35.373% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 84.419% |
| 2cureX AB (publ) | 16.62 Million SEK | -612.481% |
| I-Tech AB | 152.44 Million SEK | 22.299% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 88.365% |
| Cyxone AB (publ) | 43.65 Million SEK | -171.332% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -50.524% |
| Biosergen AB | 7.2 Million SEK | -1544.91% |
| Nanologica AB (publ) | 77.42 Million SEK | -52.979% |
| SynAct Pharma AB | 228.01 Million SEK | 48.053% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -342.589% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 91.54% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -445.78% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 50.31% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -1300.946% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -36.037% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -315.497% |